Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Major
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc. | -2.02% | 34.37 | 0.9% | $1160.45m | |
| JNJ | Johnson & Johnson | -2.61% | 127.84 | 0.7% | $889.28m | |
| MRK | Merck & Co., Inc. | -2.00% | 84.99 | 0.6% | $770.60m | |
| BMY | Bristol-Myers Squibb Company | -2.63% | 46.60 | 1.4% | $625.84m | |
| ABBV | AbbVie, Inc. | -2.24% | 66.01 | 2.3% | $624.11m | |
| LLY | Eli Lilly and Company | -1.85% | 109.55 | 1.0% | $414.75m | |
| NVS | Novartis AG Sponsored ADR | -0.63% | 88.44 | 0.2% | $173.85m | |
| AZN | AstraZeneca PLC Sponsored ADR | -1.81% | 44.59 | 1.2% | $172.00m | |
| GSK | GlaxoSmithKline plc Sponsored ADR | 0.56% | 41.21 | 0.3% | $98.85m | |
| NVO | Novo Nordisk A/S Sponsored ADR Class B | -0.85% | 52.25 | 0.1% | $73.51m | |
| SNY | Sanofi Sponsored ADR | 0.02% | 42.58 | 0.2% | $46.98m | |
| LCI | Lannett Company, Inc. | -5.98% | 6.45 | 36.6% | $4.37m | |
| AKTX | Akari Therapeutics Plc Sponsored ADR | -2.81% | 1.73 | 1.6% | $3.33m | |
| EPIX | ESSA Pharma Inc | 22.22% | 2.20 | 0.1% | $0.09m |
Company Profile
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in New York, NY.